Poolbeg Pharma (LON:POLB) Sets New 1-Year High at $12.20

Poolbeg Pharma PLC (LON:POLB)’s stock price hit a new 52-week high on Tuesday . The stock traded as high as GBX 12.20 ($0.15) and last traded at GBX 12 ($0.15), with a volume of 7049058 shares changing hands. The stock had previously closed at GBX 11.20 ($0.14).

Poolbeg Pharma Trading Up 7.1 %

The company has a market cap of £60 million, a P/E ratio of -1,182.40 and a beta of 2.27. The stock’s 50 day moving average is GBX 9.99 and its 200-day moving average is GBX 9.16.

Insiders Place Their Bets

In related news, insider Jeremy Skillington bought 154,764 shares of the firm’s stock in a transaction on Wednesday, February 21st. The stock was acquired at an average cost of GBX 11 ($0.14) per share, for a total transaction of £17,024.04 ($21,384.30). In related news, insider Jeremy Skillington acquired 154,764 shares of Poolbeg Pharma stock in a transaction dated Wednesday, February 21st. The stock was purchased at an average cost of GBX 11 ($0.14) per share, for a total transaction of £17,024.04 ($21,384.30). Also, insider Cathal Friel bought 830,000 shares of the firm’s stock in a transaction that occurred on Monday, February 19th. The stock was bought at an average cost of GBX 12 ($0.15) per share, for a total transaction of £99,600 ($125,109.91). 21.50% of the stock is owned by insiders.

Poolbeg Pharma Company Profile

Poolbeg Pharma plc operates as a biopharmaceutical company in the United Kingdom. It develops POLB 001, a p38 MAP Kinase inhibitor for the treatment of severe influenza; POLB 002, an in­licensed first­in­class broad spectrum RNA­based immunotherapy for respiratory virus infections; and POLB 003, an intramuscular vaccine to prevent Melioidosis.